Abstract |
Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor ( G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.
|
Authors | Antonio Salar, Corinne Haioun, Francesca G Rossi, Ulrich Duehrsen, Ruth Pettengell, Hans E Johnsen, Ulrich Jaeger, Gregor Verhoef, Matthias Schwenkglenks, Pamela Bacon, Kate Bendall, Pieternella J Lugtenburg |
Journal | Leukemia research
(Leuk Res)
Vol. 36
Issue 5
Pg. 548-53
(May 2012)
ISSN: 1873-5835 [Electronic] England |
PMID | 22385870
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- R-CHOP protocol
- Granulocyte Colony-Stimulating Factor
- Rituximab
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived
(adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Cyclophosphamide
(adverse effects)
- Doxorubicin
(adverse effects)
- Female
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Humans
- Lymphoma, Large B-Cell, Diffuse
(drug therapy)
- Male
- Middle Aged
- Multivariate Analysis
- Neutropenia
(chemically induced)
- Prednisone
(adverse effects)
- Risk Assessment
- Risk Factors
- Rituximab
- Vincristine
(adverse effects)
|